Niagen Bioscience, Inc. NAGE

Company Overview

Niagen Bioscience, Inc. (trading under the ticker NAGE) is a U.S.-based life sciences and nutraceutical company focused on the research, development, and commercialization of nicotinamide adenine dinucleotide (NAD⁺)–related products for healthy aging and cellular health. The company operates primarily within the dietary supplements, consumer health, and bioscience research industries. Its core commercial focus is nicotinamide riboside (NR), a patented form of vitamin B3 designed to increase NAD⁺ levels in the body, which are associated with cellular energy, metabolism, and aging-related biological processes.

The company’s primary revenue driver is the sale and licensing of its proprietary NR ingredient, marketed under the flagship consumer brand Tru Niagen®, as well as ingredient sales to third-party brands and research institutions. Niagen Bioscience serves health-conscious consumers, academic and clinical researchers, and commercial partners seeking NAD⁺-related solutions. The company positions itself as a science-first organization with a substantial portfolio of issued and pending patents around NR, supported by published clinical research and regulatory approvals in multiple jurisdictions. The business originated as ChromaDex Corporation, founded in 1999, and later evolved from a reference standards and analytical services company into a focused NAD⁺ bioscience company, culminating in a corporate rebranding to Niagen Bioscience, Inc.; the exact timing of the legal name and ticker change is reported consistently in public filings but may vary slightly across market data providers.